Clinical observation on the effect of Zengse Pill in treating patients with vitiligo of qi-stagnancy and blood-stasis syndrome type.
OBJECTIVE
To observe the clinical efficacy of Zengse Pill ( ZSP) on patients with vitiligo of qi-stagnancy and blood-stasis syndrome type (V-QB), and to preliminarily explore its mechanism of action.


METHODS
Sixty-five V-QB patients, with their diagnosis confirmed by clinical examination, were randomized by digital table method into two groups, with 31 patients in the control group and 34 in the treatment group. Cobamamide (2 tablets) was administered orally to all patients, and Psoralea tincture (a self-formulated preparation) was applied externally thrice a day. In addition, for patients in the treatment group, ZSP was given orally, at 5 pills per dose, 3 times every day. The therapeutic course for both groups was 3 months. Patients were re-examined every half-month, and changes in the skin lesions were observed and recorded. The levels of lymphocyte subsets, serum immune globulin, and complement C3 and C4 in patients were determined before and after the therapeutic course and compared with the corresponding indexes determined in 21 healthy subjects.


RESULTS
The total effective rate in the treatment group was 82.4%, which was markedly higher than that in the control group (54.8%), showing a significant difference (P<0.05). After treatment, CD(4) (+) percentage, CD(4) (+)/CD(8) (+) ratio, and blood levels of C3 and C4 increased, while CD(8) (+) percentage decreased in the treatment group (P<0.05 or P<0.01). All these indexes remained unchanged in the control group, and the respective comparisons between groups showed significant differences (P<0.01).


CONCLUSIONS
ZSP has a definite clinical effect on the treatment of V-QB but with no evident adverse reactions, and it can increase the CD(4) (+) percentage, CD(4) (+)/CD(8) (+) ratio, and the levels of serum C3 and C4, thus regulating the immunity of the organism, which might be one of its mechanisms of action.
SHI
Nian
N
Department of Dermatology, the First Hospital of Huangshi City, Huangshi, Hubei (435001), China.
CHEN
Yong-jun
YJ
WANG
Jian
J
NI
Hao
H
D000293:Adolescent; D000328:Adult; D016516:CD4-CD8 Ratio; D003176:Complement C3 / Q000032:analysis; D003181:Complement C4 / Q000032:analysis; D004365:Drugs, Chinese Herbal / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007136:Immunoglobulins / Q000097:blood; D016131:Lymphocyte Subsets; D008297:Male; D008516:Medicine, Chinese Traditional; D008875:Middle Aged; D019413:Qi; D014820:Vitiligo / Q000188:drug therapy* / Q000276:immunology
D003176:Complement C3; D003181:Complement C4; D004365:Drugs, Chinese Herbal; D007136:Immunoglobulins